{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:03:25Z","timestamp":1791644605505,"version":"4.3.4"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Dutch Charity Foundation KiKa"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>What is the impact of the EuroNet-PHL-C2 treatment for boys with classical Hodgkin lymphoma (cHL) on semen parameters?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>More than half of the patients (52%, n\u2009=\u200916\/31) had oligozoospermia or azoospermia at 2\u2009years from cHL diagnosis; particularly boys treated for advanced-stage cHL had low sperm counts and motility.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>Chemotherapy and radiotherapy to the inguinal region or testes can impair spermatogenesis and result in reduced fertility. The EuroNet-PHL-C2 trial aims to minimize radiotherapy in standard childhood cHL treatment, by intensifying chemotherapy. The present study aims to assess the (gonadotoxic) impact of this treatment protocol on semen parameters and reproductive hormones in boys aged \u226418\u2009years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>This international, prospective, multi-centre cohort study was an add-on study to the randomized phase-3 EuroNet-PHL-C2 trial, where the efficacy of standard cHL treatment with OEPA-COPDAC-28 (OEPA: vincristine, etoposide, prednisone, and doxorubicin; COPDAC-28: cyclophosphamide, vincristine, prednisone, and dacarbazine) was compared to intensified OEPA-DECOPDAC-21 chemotherapy (DECOPDAC-21: COPDAC with additional doxorubicin and etoposide and 25% more cyclophosphamide). Patients were recruited between January 2017 and September 2021.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                  <jats:p>Eligibility criteria included male patients, diagnosed with classical HL before or at the age of 18\u2009years, and treated according to the EuroNet-PHL-C2 protocol in any of the 18 participating sites in the Netherlands, Germany, Belgium, Czech Republic, and Austria. Sperm parameters (sperm concentration, progressive motility, sperm volume, and calculated total motile sperm count) were assessed at diagnosis and 2\u2009years after diagnosis in (post)pubertal boys. Laboratory measurements (serum follicle-stimulating hormone (FSH) and inhibin B) were performed in samples drawn at diagnosis, during treatment (2\u20133 times), and at 2 years post-diagnosis, and (age-adjusted) analyses were conducted separately for pre-pubertal and (post)pubertal boys. Outcomes were compared between the treatment levels (TL1, TL2, and TL3) and consolidation treatment schemes (COPDAC-28 and DECOPDAC-21).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>In total, 101 boys were included in the present analysis: 73 were (post)pubertal (median age 15.4\u2009years, (IQR 14.4; 16.6), 10 TL1, 29 TL2, 34 TL3, 62% of TL2\/3 patients received COPDAC-28) and 28 boys were pre-pubertal (median age 9.6\u2009years (IQR 6.6; 11.4), 4 TL1, 7 TL2, 17 TL3, 38% of TL2\/3 patients received COPDAC-28). The study included six boys who had received pelvic radiotherapy; none were irradiated in the inguinal or testicular area. At diagnosis, 48 (post)pubertal boys delivered semen for cryopreservation; 19 (40%) semen samples were oligospermic and 4 (8%) were azoospermic. Low sperm concentration (&amp;lt;15\u00a0mil\/ml) appeared to be related to the HL disease itself, with a higher prevalence in boys who presented with B symptoms (76% vs 26%, aOR 2.3 (95% CI 1.0; 3.8), P\u2009=\u20090.001) compared to those without such symptoms. At 2\u00a0-years\u00a0post-diagnosis, 31 boys provided semen samples for analysis, of whom 12 (39%) boys had oligozoospermia and 4 (13%) had azoospermia, while 22 boys (71%) had low total motile sperm counts (TMSC) (&amp;lt;20\u00a0mil). Specifically, the eight boys in the TL3 group treated with DECOPDAC-21 consolidation had low sperm counts and low progressive motility after 2\u2009years (i.e. median sperm count 1.4\u2009mil\/ml (IQR &amp;lt;0.1; 5.3), n\u2009=\u20097 (88%), low sperm concentration, low median progressive motility 16.5% (IQR 0.0; 51.2), respectively). Age-adjusted serum FSH levels were significantly raised and inhibin B levels (and inhibin B:FSH ratios) were decreased during chemotherapy in (post)pubertal boys, with subsequent normalization in 80% (for FSH) and 60% (for inhibin B) of boys after 2\u2009years. Only 4 out of the 14 (post)pubertal boys (29%) with low sperm concentrations after 2\u2009years had elevated FSH (&amp;gt;7.6\u2009IU\/l), while 7 (50%) had low inhibin B levels (&amp;lt;100\u00a0ng\/l). In pre-pubertal boys, reproductive hormones were low overall and remained relatively stable during chemotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>The present analyses included sperm and laboratory measurements up to 2 years post-diagnosis. Long-term reproductive outcomes and potential recovery of spermatogenesis remain unknown, while recovery was reported up to 5- or even 10-year post-chemotherapy in previous studies.<\/jats:p>\n                  <jats:p>Boys who were pre-pubertal at diagnosis were still too young and\/or physically not able to deliver semen after 2\u2009years and we could not assess a potential difference in gonadotoxicity according to pubertal state at the time of treatment. Overall, the statistical power of the analyses on sperm concentration and quality after 2\u2009years was limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>Results of the semen analyses conducted among the 31 boys who had provided a semen sample at 2 years post-treatment were generally poor. However, additional long-term and adequately powered data are crucial to assess the potential recovery and clinical impact on fertility. The participating boys will be invited to deliver a semen sample after 5 years. Until these data become available, benefits of intensified chemotherapy in cHL treatment to reduce radiotherapy and lower risk for development of secondary tumours should be carefully weighed against potentially increased risk of other late effects, such as diminished fertility due to the increased chemotherapy burden. Boys with newly diagnosed cHL should be encouraged to deliver sperm for cryopreservation whenever possible. However, patients and clinicians should also realize that the overall state of disease and inflammatory milieu of cHL can negatively affect sperm quality and thereby reduce chance of successful fertility preservation. Furthermore, the measurement of FSH and inhibin B appears to be of low value in predicting low sperm quality at two years from cHL treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                  <jats:p>This study was funded by the Dutch charity foundation KiKa (project 257) that funds research on all forms of childhood cancer. C.M.-K., D.K., W.H.W., D.H., MC, A.U., and A.B. were involved in the development of the EuroNet-PHL-C2 regimen. The other authors declare no potential conflict of interest.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                  <jats:p>N\/A.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humrep\/deae204","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T05:48:40Z","timestamp":1726033720000},"page":"2411-2422","source":"Crossref","is-referenced-by-count":12,"title":["Semen analysis and reproductive hormones in boys with classical Hodgkin lymphoma treated according to the EuroNet-PHL-C2 protocol"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9879-4678","authenticated-orcid":false,"given":"K C E","family":"Drechsel","sequence":"first","affiliation":[{"name":"Pediatric Oncology, Cancer Center Amsterdam, Emma Children\u2019s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam,","place":["The Netherlands"]},{"name":"Department of Paediatric Haemato-Oncology, Princess M\u00e1xima Center for Pediatric Oncology , Utrecht,","place":["The Netherlands"]},{"name":"Cancer Center Amsterdam, Treament and quality of life, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7699-0931","authenticated-orcid":false,"given":"S L","family":"Broer","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine & Gynecology, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0362-7709","authenticated-orcid":false,"given":"H M K","family":"van Breda","sequence":"additional","affiliation":[{"name":"Department of Urology, University Medical Centre Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9042-2404","authenticated-orcid":false,"given":"F S","family":"Stoutjesdijk","sequence":"additional","affiliation":[{"name":"Pediatric Oncology, Cancer Center Amsterdam, Emma Children\u2019s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8870-6539","authenticated-orcid":false,"given":"E","family":"van Dulmen-den Broeder","sequence":"additional","affiliation":[{"name":"Pediatric Oncology, Cancer Center Amsterdam, Emma Children\u2019s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6482-1823","authenticated-orcid":false,"given":"A","family":"Beishuizen","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haemato-Oncology, Princess M\u00e1xima Center for Pediatric Oncology , Utrecht,","place":["The Netherlands"]},{"name":"Department of Haematology\/Oncology, Erasmus MC\u2014Sophia Children\u2019s Hospital , Rotterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-5674","authenticated-orcid":false,"given":"W H","family":"Wallace","sequence":"additional","affiliation":[{"name":"Department of Haematology\/Oncology, Royal Hospital for Sick Children , Edinburgh,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"K\u00f6rholz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Universit\u00e4tsklinikum Giessen und Marburg GmbH, Standort Giessen\u2014Zentrum f\u00fcr Kinderheilkunde und Jugendmedizin , Giessen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8205-8665","authenticated-orcid":false,"given":"C","family":"Mauz-K\u00f6rholz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Universit\u00e4tsklinikum Giessen und Marburg GmbH, Standort Giessen\u2014Zentrum f\u00fcr Kinderheilkunde und Jugendmedizin , Giessen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3224-1610","authenticated-orcid":false,"given":"D","family":"Hasenclever","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Medizinische Informatik, Statistik und Epidemiologie, Universit\u00e4t Leipzig , Leipzig,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7191-588X","authenticated-orcid":false,"given":"M","family":"Cepelova","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, University Hospital Motol and 2nd Medical Faculty Charles University , Prague 5,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5644-424X","authenticated-orcid":false,"given":"A","family":"Uyttebroeck","sequence":"additional","affiliation":[{"name":"Paediatric Haemato-Oncology, University Hospitals of Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Ronceray","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, St. Anna Children\u2019s Hospital, Medical University of Vienna , Wien,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9617-1020","authenticated-orcid":false,"given":"J W R","family":"Twisk","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-8475","authenticated-orcid":false,"given":"G J L","family":"Kaspers","sequence":"additional","affiliation":[{"name":"Pediatric Oncology, Cancer Center Amsterdam, Emma Children\u2019s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam,","place":["The Netherlands"]},{"name":"Cancer Center Amsterdam, Treament and quality of life, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-0795","authenticated-orcid":false,"given":"M A","family":"Veening","sequence":"additional","affiliation":[{"name":"Pediatric Oncology, Cancer Center Amsterdam, Emma Children\u2019s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam,","place":["The Netherlands"]},{"name":"Cancer Center Amsterdam, Treament and quality of life, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"2024110408195716100_deae204-B1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1439-0272.2010.01077.x","article-title":"Evaluation of semen quality in patients with malignancies referred for sperm banking before cancer treatment","volume":"43","author":"Amirjannati","year":"2011","journal-title":"Andrologia"},{"key":"2024110408195716100_deae204-B2","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/humrep\/12.4.746","article-title":"Physiological relationships between inhibin B, follicle stimulating hormone secretion and spermatogenesis in normal men and response to gonadotrophin suppression by exogenous testosterone","volume":"12","author":"Anderson","year":"1997","journal-title":"Hum Reprod"},{"key":"2024110408195716100_deae204-B3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0303-7207(01)00520-2","article-title":"Serum inhibin B levels during male childhood and puberty","volume":"180","author":"Andersson","year":"2001","journal-title":"Mol Cell Endocrinol"},{"key":"2024110408195716100_deae204-B4","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1210\/jc.2003-032148","article-title":"Serum inhibin B and follicle-stimulating hormone levels as tools in the evaluation of infertile men: significance of adequate reference values from proven fertile men","volume":"89","author":"Andersson","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2024110408195716100_deae204-B5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/1097-0142(19840715)54:2<215::AID-CNCR2820540207>3.0.CO;2-#","article-title":"Hodgkin\u2019s disease in children. Results of therapy in a mixed group of 178 clinical and pathologically staged patients over 13 years","volume":"54","author":"Bayle-Weisgerber","year":"1984","journal-title":"Cancer"},{"key":"2024110408195716100_deae204-B6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.rbmo.2011.11.015","article-title":"Sperm cryopreservation before cancer treatment: a 15-year monocentric experience","volume":"24","author":"Bizet","year":"2012","journal-title":"Reprod Biomed Online"},{"key":"2024110408195716100_deae204-B7","first-page":"227","article-title":"\u201cHow to count sperm properly\u201d: checklist for acceptability of studies based on human semen analysis","volume":"31","author":"Bj\u00f6rndahl","year":"2016","journal-title":"Hum Reprod"},{"key":"2024110408195716100_deae204-B8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1515\/JPEM.2004.17.6.879","article-title":"Decreased serum inhibin B\/FSH ratio as a marker of Sertoli cell function in male survivors after chemotherapy in childhood and adolescence","volume":"17","author":"Bordallo","year":"2004","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2024110408195716100_deae204-B9","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical Hodgkin lymphoma","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet"},{"key":"2024110408195716100_deae204-B10","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00432-016-2124-5","article-title":"Gonadal status in long-term male survivors of childhood cancer","volume":"142","author":"Brignardello","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"2024110408195716100_deae204-B11","first-page":"325","article-title":"Male fertility following childhood cancer: current concepts and future therapies","volume":"5","author":"Brougham","year":"2003","journal-title":"Asian J Androl"},{"key":"2024110408195716100_deae204-B12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/and.12451","article-title":"Do malignant diseases affect semen quality? Sperm parameters of men with cancers","volume":"48","author":"Caponecchia","year":"2016","journal-title":"Andrologia"},{"key":"2024110408195716100_deae204-B13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/humupd\/dmp048","article-title":"World Health Organization reference values for human semen characteristics","volume":"16","author":"Cooper","year":"2010","journal-title":"Hum Reprod Update"},{"key":"2024110408195716100_deae204-B14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1046\/j.0300-0664.2001.01448.x","article-title":"Inhibin B in boys from birth to adulthood: relationship with age, pubertal stage, FSH and testosterone","volume":"56","author":"Crofton","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024110408195716100_deae204-B15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.1984.2.6.571","article-title":"Recovery of spermatogenesis after treatment for Hodgkin\u2019s disease: limiting dose of MOPP chemotherapy","volume":"2","author":"da Cunha","year":"1984","journal-title":"J Clin Oncol"},{"key":"2024110408195716100_deae204-B16","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.fertnstert.2014.11.012","article-title":"Sperm cryopreservation in adolescents and young adults with cancer: results of the French National Sperm Banking Network (CECOS)","volume":"103","author":"Daudin","year":"2015","journal-title":"Fertil Steril"},{"key":"2024110408195716100_deae204-B17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejca.2023.02.019","article-title":"Anthracycline-induced cardiotoxicity\u2014are we about to clear this hurdle?","volume":"185","author":"Dempke","year":"2023","journal-title":"Eur J Cancer"},{"key":"2024110408195716100_deae204-B18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/humupd\/dmad002","article-title":"Reproductive ability in survivors of childhood, adolescent and young adult Hodgkin lymphoma: a review","volume":"29","author":"Drechsel","year":"2023","journal-title":"Hum Reprod Update"},{"key":"2024110408195716100_deae204-B19","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/humrep\/deae112","article-title":"The impact of treatment for childhood classical Hodgkin lymphoma according to the EuroNet-PHL-C2 protocol on serum anti-M\u00fcllerian hormone","volume":"39","author":"Drechsel","year":"2024","journal-title":"Hum Reprod"},{"key":"2024110408195716100_deae204-B20","volume-title":"Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescent: EuroNet-PHL-C2","author":"European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL)","year":"2015"},{"key":"2024110408195716100_deae204-B21","doi-asserted-by":"crossref","first-page":"e28709","DOI":"10.1002\/pbc.28709","article-title":"Effects of treatments on gonadal function in long-term survivors of pediatric hematologic malignancies: a cohort study","volume":"67","author":"Felicetti","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"2024110408195716100_deae204-B22","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1210\/jcem-34-6-1003","article-title":"Relationship between spermatogenesis and serum gonadotropin levels in azoospermia and oligospermia","volume":"34","author":"Franchimont","year":"1972","journal-title":"J Clin Endocrinol Metab"},{"key":"2024110408195716100_deae204-B23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/humrep\/dead230","article-title":"Maternal pre-pregnancy BMI and reproductive health in adult sons: a study in the Danish National Birth Cohort","volume":"39","author":"Gaml-S\u00f8rensen","year":"2024","journal-title":"Hum Reprod"},{"key":"2024110408195716100_deae204-B58","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/pbc.24679","article-title":"The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study","volume":"61","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"2024110408195716100_deae204-B24","doi-asserted-by":"crossref","first-page":"hoaa016","DOI":"10.1093\/hropen\/hoaa016","article-title":"Fertility preservation in boys: recent developments and new insights","volume":"2020","author":"Goossens","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2024110408195716100_deae204-B25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-030-32482-7_1","volume-title":"Hodgkin Lymphoma: A Comprehensive Overview","author":"Hjalgrim","year":"2020"},{"key":"2024110408195716100_deae204-B26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/pbc.20172","article-title":"Fertility in males treated for Hodgkins disease with COPP\/ABV hybrid","volume":"44","author":"Hobbie","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"2024110408195716100_deae204-B27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jncimonographs\/lgi003","article-title":"Spermatogenesis after cancer treatment: damage and recovery","volume":"34","author":"Howell","year":"2005","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2024110408195716100_deae204-B28","volume-title":"IBM SPSS Statistics for Windows, Version 28.0","author":"IBM Corp","year":"2021"},{"key":"2024110408195716100_deae204-B29","doi-asserted-by":"crossref","first-page":"e0181377","DOI":"10.1371\/journal.pone.0181377","article-title":"Follicle stimulating hormone is an accurate predictor of azoospermia in childhood cancer survivors","volume":"12","author":"Kelsey","year":"2017","journal-title":"PLoS One"},{"key":"2024110408195716100_deae204-B30","doi-asserted-by":"crossref","first-page":"e0153843","DOI":"10.1371\/journal.pone.0153843","article-title":"A normative model of serum Inhibin B in young males","volume":"11","author":"Kelsey","year":"2016","journal-title":"PLoS One"},{"key":"2024110408195716100_deae204-B31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12958-020-00686-w","article-title":"FSH regulates RA signaling to commit spermatogonia into differentiation pathway and meiosis","volume":"19","author":"Khanehzad","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"key":"2024110408195716100_deae204-B32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bjh.17767","article-title":"In male Hodgkin lymphoma patients, impaired fertility may be improved by non-gonadotoxic therapy","volume":"196","author":"Laddaga","year":"2021","journal-title":"Br J Haematol"},{"key":"2024110408195716100_deae204-B33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/humrep\/dead004","article-title":"Childhood cancer and hematological disorders negatively affect spermatogonial quantity at diagnosis: a retrospective study of a male fertility preservation cohort","volume":"38","author":"Masliukaite","year":"2023","journal-title":"Hum Reprod"},{"key":"2024110408195716100_deae204-B34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","article-title":"Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial","volume":"23","author":"Mauz-K\u00f6rholz","year":"2022","journal-title":"Lancet Oncol"},{"key":"2024110408195716100_deae204-B35","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/eje.0.1450561","article-title":"Inhibin B in male reproduction: pathophysiology and clinical relevance","volume":"145","author":"Meachem","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"2024110408195716100_deae204-B36","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.fertnstert.2013.08.010","article-title":"Effects of chemotherapy and radiotherapy on spermatogenesis in humans","volume":"100","author":"Meistrich","year":"2013","journal-title":"Fertil Steril"},{"key":"2024110408195716100_deae204-B37","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.maturitas.2015.02.091","article-title":"A normative model of Inhibin B in young males","volume":"81","author":"Miles","year":"2015","journal-title":"Maturitas"},{"key":"2024110408195716100_deae204-B38","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S1470-2045(20)30582-9","article-title":"Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"22","author":"Mulder","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024110408195716100_deae204-B39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/beem.2002.0183","article-title":"Disturbance of pubertal development after cancer treatment","volume":"16","author":"M\u00fcller","year":"2002","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2024110408195716100_deae204-B40","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/0360-3016(90)90007-7","article-title":"Gonadal status and reproductive function following treatment for Hodgkin\u2019s disease in childhood: the Stanford experience","volume":"19","author":"Ortin","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024110408195716100_deae204-B41","first-page":"315","article-title":"Gonadal function in children with nephrosis treated with cyclophosphamide","volume":"129","author":"Pennisi","year":"1975","journal-title":"Am J Dis Child"},{"key":"2024110408195716100_deae204-B42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/07853890310004084","article-title":"Inhibin B: a novel marker of spermatogenesis","volume":"35","author":"Pierik","year":"2003","journal-title":"Ann Med"},{"key":"2024110408195716100_deae204-B43","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0015-0282(16)48624-3","article-title":"Evaluation of semen and pituitary gonadotropin function in men with untreated Hodgkin\u2019s disease","volume":"43","author":"Ragni","year":"1985","journal-title":"Fertil Steril"},{"key":"2024110408195716100_deae204-B44","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1530\/eje.0.1420150","article-title":"Signaling between the pituitary gland and the testes: inverse relationship between serum FSH and inhibin B concentrations in boys in early puberty","volume":"142","author":"Raivio","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"2024110408195716100_deae204-B45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2605.2010.01058.x","article-title":"High risk of azoospermia in men treated for childhood cancer","volume":"34","author":"Romerius","year":"2010","journal-title":"Int J Androl"},{"key":"2024110408195716100_deae204-B46","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1023\/A:1012464703805","article-title":"Male gonadal dysfunction in patients with Hodgkin\u2019s disease prior to treatment","volume":"12","author":"Rueffer","year":"2001","journal-title":"Ann Oncol"},{"key":"2024110408195716100_deae204-B47","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3390\/jcm9041014","article-title":"Follicle-stimulating hormone (FSH) action on spermatogenesis: a focus on physiological and therapeutic roles","volume":"9","author":"Santi","year":"2020","journal-title":"J Clin Med"},{"key":"2024110408195716100_deae204-B48","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"2024110408195716100_deae204-B49","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0022-5347(05)65411-0","article-title":"The role of testicular biopsy in the modern management of male infertility","volume":"167","author":"Schoor","year":"2002","journal-title":"J Urol"},{"key":"2024110408195716100_deae204-B50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1056\/NEJM197807062990103","article-title":"Gynecomastia and gonadal fysfunction in adolescent boys treated with combination chemotherapy for Hodgkin\u2019s disease","volume":"299","author":"Sherins","year":"1978","journal-title":"N Engl J Med"},{"key":"2024110408195716100_deae204-B51","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/annonc\/mdn376","article-title":"Assessment of male fertility in patients with Hodgkin\u2019s lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials","volume":"19","author":"Sieniawski","year":"2008","journal-title":"Ann Oncol"},{"key":"2024110408195716100_deae204-B52","doi-asserted-by":"crossref","first-page":"R69","DOI":"10.1530\/EC-17-0382","article-title":"Cancer treatment in childhood and testicular function: the importance of the somatic environment","volume":"7","author":"Stukenborg","year":"2018","journal-title":"Endocr Connect"},{"key":"2024110408195716100_deae204-B53","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/humrep\/15.9.1985","article-title":"Follow-up of sperm concentration and motility in patients with lymphoma","volume":"15","author":"Tal","year":"2000","journal-title":"Hum Reprod"},{"key":"2024110408195716100_deae204-B54","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.fertnstert.2007.08.006","article-title":"Semen cryopreservation in pubertal boys before gonadotoxic treatment and the role of endocrinologic evaluation in predicting sperm yield","volume":"90","author":"van Casteren","year":"2008","journal-title":"Fertil Steril"},{"key":"2024110408195716100_deae204-B55","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/s41591-023-02514-1","article-title":"Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer","volume":"29","author":"Wang","year":"2023","journal-title":"Nat Med"},{"key":"2024110408195716100_deae204-B56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-3-540-78355-8_2","volume-title":"Andrology: Male Reproductive Health and Dysfunction","author":"Weinbauer","year":"2010"},{"key":"2024110408195716100_deae204-B57","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2478\/v10019-010-0034-8","article-title":"Gonadal function in patients treated for Hodgkin\u2019s disease in childhood","volume":"44","author":"Zaletel","year":"2010","journal-title":"Radiol Oncol"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/39\/11\/2411\/60241811\/deae204.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/39\/11\/2411\/60241811\/deae204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T08:21:19Z","timestamp":1730708479000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/39\/11\/2411\/7754836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":58,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,9,10]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deae204","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,9,10]]}}}